Results 11 to 20 of about 21,209 (213)

Osteoprotegerin in Cardiometabolic Disorders [PDF]

International Journal of Endocrinology, 2015
Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for CVD.
Pérez de Ciriza, C., Lawrie, A., Varo, N.   +2 more
openaire   +5 more sources

Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study.

PLoS ONE, 2016
Osteoprotegerin, a potent osteoclast activation inhibitor, decreases bone resorption and positively affects bone mineral density. This study examined the association between serum osteoprotegerin levels and bone loss in patients with chronic kidney ...
Chang Seong Kim, Eun Hui Bae, Seong Kwon Ma, Seung Hyeok Han, Kyu Hun Choi, Joongyub Lee, Dong Wan Chae, Kook-Hwan Oh, Curie Ahn, Soo Wan Kim, Representatives of the KNOW-CKD Investigator Group   +10 more
doaj   +1 more source

Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study

Medicina, 2022
Background and objective: There is limited information as to the association of several key bone markers with bone mineral density (BMD) in understudied ethnic groups. This study investigated the relationship between circulating levels of osteoprotegerin
Osama E. Amer, Kaiser Wani, Mohammed G. A. Ansari, Abdullah M. Alnaami, Naji Aljohani, Saba Abdi, Syed D. Hussain, Nasser M. Al-Daghri, Majed S. Alokail   +8 more
doaj   +1 more source

OSTEOPROTEGERIN AND BONE DENSITY [PDF]

Biomedical Papers, 2001
Aim of study was determine if a correlation exists between bone mass density and concentration of osteoprotegerin. We examined the group of 199 patients of mean age of 63 years. Of the group under study, 31 patients had normal bone density (T score > -1 and < 1) and 168 probands had osteopenia or osteoporosis (T < -1).
D, Stejskal, M, Zurek, J, Bartek, L, Jedelský, V, Růzicka   +4 more
openaire   +2 more sources

Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes

Cardiovascular Diabetology, 2013
Background Osteoprotegerin is a member of the tumor necrosis factor-related family and inhibits RANK stimulation of osteoclast formation as a soluble decoy receptor.
Aoki Atsushi, Murata Miho, Asano Tomoko, Ikoma Aki, Sasaki Masami, Saito Tomoyuki, Otani Taeko, Jinbo Sachimi, Ikeda Nahoko, Kawakami Masanobu, Ishikawa San-e   +10 more
doaj   +1 more source

Serum Osteoprotegerin and Carotid Intima-Media Thickness Are Related to High Arterial Stiffness in Heart Failure with Reduced Ejection Fraction

Diagnostics, 2021
Arterial stiffness (AS) is a complex vascular phenomenon with consequences for central hemodynamics and left-ventricular performance. Circulating biomarkers have been associated with AS; however, their value in heart failure is poorly characterized.
Lajos Fehérvári, Attila Frigy, Lóránd Kocsis, István Adorján Szabó, Timea Magdolna Szabo, Melinda Urkon, Zita Jakó, Előd Ernő Nagy   +7 more
doaj   +1 more source

Interleukin-19 promotes bone resorption by suppressing osteoprotegerin expression in BMSCs in a lipopolysaccharide-induced bone loss mouse model

Bone & Joint Research, 2023
Aims: Osteoporosis is characterized by decreased trabecular bone volume, and microarchitectural deterioration in the medullary cavity. Interleukin-19 (IL-19), a member of the IL-10 family, is an anti-inflammatory cytokine produced primarily by ...
Zhicheng Dai, Yanan Chen, Enjun He, Hongjie Wang, Weihong Guo, Zhenkai Wu, Kai Huang, Qinghua Zhao   +7 more
doaj   +1 more source

OSTEOPROTEGERIN, RANK, RANKL [PDF]

Biomedical Papers, 2001
Osteoprotegerin, RANK (Receptor Activator of Nuclear factor kappa B) and RANKL (Receptor Activator of Nuclear faktor kappa B ligand) became the aim of intensive research. RANK is considered as a hematopoietic surface receptor controlling osteoclastogenesis and calcium metabolism.
D, Stejskal, J, Bartek, R, Pastorková, V, Růzicka, I, Oral, D, Horalík   +5 more
openaire   +2 more sources

The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption [PDF]

Journal of Bone and Mineral Research, 2000
Abstract Although multiple hormones and cytokines regulate various aspects of osteoclast formation, the final two effectors are osteoprotegerin ligand (OPG-L)/osteoclast differentiation factor (ODF), a recently cloned member of the tumor necrosis factor superfamily, and macrophage colony–stimulating factor.
L C, Hofbauer, S, Khosla, C R, Dunstan, D L, Lacey, W J, Boyle, B L, Riggs   +5 more
openaire   +2 more sources

Serum OPG and RANKL Levels as Risk Factors for the Development of Cardiovascular Calcifications in End-Stage Renal Disease Patients in Hemodialysis

Life, 2023
Cardiovascular calcifications (CVC) are frequently observed in chronic kidney disease (CKD) patients and contribute to their cardiovascular mortality. The aim of the present study was to investigate the impact of osteoprotegerin (OPG)/Receptor Activator ...
Michalis Spartalis, Efstratios Kasimatis, Eleni Liakou, Erasmia Sampani, Georgios Lioulios, Michalis Christodoulou, Stamatia Stai, Eleni Moysidou, George Efstratiadis, Aikaterini Papagianni   +9 more
doaj   +1 more source